Literature DB >> 27267495

Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study.

Juan P Brito1, Stephanie Schilz2, Naykky Singh Ospina1, Rene Rodriguez-Gutierrez1,3, Spyridoula Maraka1, Lindsey R Sangaralingham2, Victor M Montori1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27267495     DOI： 10.1089/thy.2016.0222

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  23 in total

1.  Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment.

Authors:  M Žarković; W Wiersinga; P Perros; L Bartalena; S Donati; O Okosieme; D Morris; N Fichter; J Lareida; C Daumerie; M-C Burlacu; G J Kahaly; S Pitz; B Beleslin; J Ćirić; G Ayvaz; O Konuk; F B Törüner; M Salvi; D Covelli; N Curro; L Hegedüs; T Brix
Journal:  J Endocrinol Invest       Date:  2020-06-10       Impact factor: 4.256

2.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

3.  When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?

Authors:  Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim
Journal:  Endocrine       Date:  2019-06-24       Impact factor: 3.633

4.  Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study.

Authors:  P Premoli; M L Tanda; E Piantanida; G Veronesi; D Gallo; E Masiello; S Rosetti; C Cusini; F Boi; J Bulla; R Rodia; S Mariotti; V Capelli; M Rotondi; F Magri; L Chiovato; R Rocchi; M C Campopiano; R Elisei; P Vitti; F Barbato; T Pilli; M G Castagna; F Pacini; L Bartalena
Journal:  J Endocrinol Invest       Date:  2019-07-20       Impact factor: 4.256

5.  Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.

Authors:  E Masiello; G Veronesi; D Gallo; P Premoli; E Bianconi; S Rosetti; C Cusini; J Sabatino; S Ippolito; E Piantanida; M L Tanda; L Chiovato; W M Wiersinga; L Bartalena
Journal:  J Endocrinol Invest       Date:  2018-06-26       Impact factor: 4.256

6.  Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.

Authors:  Brian Hung-Hin Lang; Yu-Cho Woo; Keith Wan-Hang Chiu
Journal:  Eur Radiol       Date:  2019-06-17       Impact factor: 5.315

7.  Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.

Authors:  Ari Song; Su Jin Kim; Min-Sun Kim; Jiyeon Kim; Insung Kim; Ga Young Bae; Eunseop Seo; Young Seok Cho; Joon Young Choi; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-14       Impact factor: 5.555

8.  Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression.

Authors:  S Ippolito; C Cusini; P Lasalvia; F Gianfagna; G Veronesi; D Gallo; E Masiello; P Premoli; J Sabatino; A Mercuriali; A Lai; E Piantanida; M L Tanda; L Bartalena
Journal:  J Endocrinol Invest       Date:  2020-12-21       Impact factor: 4.256

9.  2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.

Authors:  George J Kahaly; Luigi Bartalena; Lazlo Hegedüs; Laurence Leenhardt; Kris Poppe; Simon H Pearce
Journal:  Eur Thyroid J       Date:  2018-07-25

10.  Antithyroid Drug Treatment in Graves' Disease.

Authors:  Jae Hoon Chung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.